Owned by the Association for International Promotion & Study in Tumors (APSIT)
TRF2 as novel marker of tumor response to taxane-based therapy: from mechanistic insight to clinical implication
Breast Cancer (BC) can be classified, due to its heterogeneity, into multiple subtypes that differ for prognosis and clinical management. Notably, triple negative breast cancer (TNBC) – the most aggressive BC ...